曲伏噻吗(Travoprost/Timolol Maleate) - 药物靶点：PTGFR x β-adrenoceptors_在研适应症：青光眼，开角型青光眼，高眼压症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

DuoTrav APS、DuoTrav BAK、DuoTrav PQ

+ [11]

靶点

PTGFR x β-adrenoceptors

作用方式

激动剂、拮抗剂

作用机制

PTGFR激动剂(前列腺素FP受体激动剂)、β-adrenoceptors拮抗剂(β-肾上腺素能受体家族拮抗剂)

治疗领域

眼部疾病

在研适应症

青光眼开角型青光眼高眼压症

非在研适应症-

原研机构

Alcon AG

在研机构

Novartis Europharm Ltd.Novartis Pharmaceuticals Australia Pty Ltd.

Novartis Pharmaceuticals Corp.

+ [1]

非在研机构

Alcon Research Ltd.

最高研发阶段批准上市

首次获批日期

欧盟 (2006-04-23),

开角型青光眼高眼压症

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C39H59F3N4O9S

InChIKeyKJNUGXGYVXURJB-DDANCUEQSA-N

CAS号874755-80-3

关联

36

项与曲伏噻吗相关的临床试验

NCT02730871

/ Terminated临床4期

Safety and Efficacy With Twice Daily Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA®) as an Adjunctive Therapy to Travoprost 0.004%/Timolol 0.5% (DUOTRAV®)

The purpose of this study is to evaluate the additive intraocular pressure (IOP) lowering effect of Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA®) dosed twice daily (BID) when added to Travoprost 0.004%/Timolol 0.5% (DUOTRAV®) in subjects with open-angle glaucoma or ocular hypertension.

开始日期2016-06-24

申办/合作机构

Alcon Research Ltd.

NCT03966560

/ Completed临床4期IIT

Choroidal Thickness and Its Correlations With Ocular Parameters in Cases With Primary Open-angle Glaucoma

Glaucoma is one of the leading causes of blindness worldwide that is a chronic public health problem. Unfortunately, glaucoma can be diagnosed when the disease reaches a certain level in today's conditions. The aim of this study was to investigate the diagnostic methods that can diagnose glaucoma before it reaches the advanced level and to identify pathophysiological processes. In this study, choroidal thickness was investigated in primary open-angle glaucoma cases and its correlations with OCT and multifocal ERG parameters were evaluated.

开始日期2014-01-01

申办/合作机构

Afyon Kocatepe University

NCT02003391

/ Completed临床4期

Prospective, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of DuoTrav® in Patients Previously Uncontrolled on a Beta-blocker

The purpose of this study is to demonstrate superior intraocular pressure (IOP) control with travoprost 0.004% / timolol 0.5% compared to beta-blocker monotherapy in participants with open-angle glaucoma or ocular hypertension.

开始日期2013-12-01

申办/合作机构

Alcon Research Ltd.

100 项与曲伏噻吗相关的临床结果

登录后查看更多信息

100 项与曲伏噻吗相关的转化医学

登录后查看更多信息

100 项与曲伏噻吗相关的专利（医药）

登录后查看更多信息

89

项与曲伏噻吗相关的文献（医药）

2024-08-01·VACCINE

Single immunization of non-adjuvanted recombinant TTFC-mi3 nanoparticle vaccine elicited a rapid and potent protective immunity against tetanus

Article

作者: Zhang, Yi ; Luo, Ping ; Wu, Meilin ; Cheng, Xin ; Li, Yuhang ; Wang, Yi ; Gu, Jiang ; He, Qinggang ; Li, Xiaoyan ; Chen, Yuan ; Wan, Jiqing

The conventional inactivated tetanus toxin plays an instrumental role in preventing tetanus. Nevertheless, the challenges associated with its production process, the potential for adverse reactions, and reduced effectiveness in vulnerable populations such as neonates and the elderly rise the need for a novel tetanus toxin vaccine. Recombinant subunit vaccine offer a viable solution, and the tetanus toxin fragment C (TTFC) is emerging as a promising candidate. In this study, through spontaneous isopeptide bond formation we conjugated the recombinant TTFC to self-assembled mi3 nanoparticle, which derived from an optimized KDPG aldolase, and generated the TTFC-mi3 protein nanoparticle vaccine. We found that TTFC-mi3 is stable, uniform spherical nanoparticles. Comparing with the free TTFC alone, TTFC-mi3 enhances the uptake and subsequent activation of dendric cells (DCs). In addition, a single dose of adjuvant-free TTFC-mi3 elicited a more rapid and potent protective immunity in mice. Moreover, TTFC-mi3 is of favorable safety in vitro and in vivo. Our findings indicate that TTFC-mi3 is a rapid-response, non-aluminum-adjuvanted vaccine against tetanus.

2022-09-05·Journal of epidemiology3区 · 医学

Association of the Time to First Cigarette and the Prevalence of Chronic Respiratory Diseases in Chinese Elderly Population

3区 · 医学

ArticleOA

作者: Lou, Yiling ; Jiang, Heng ; Guo, Yingying ; Tian, Qingfeng ; Cao, Shiyi ; Gan, Yong ; Wang, Chao ; Zhu, Yi ; Lu, Zuxun

BACKGROUND:

Increasing number of studies have suggested the time to first cigarette after waking (TTFC) have significant positive effect on respiratory diseases. However, few of them focused on the Chinese population. This study aims to estimate the impact of TTFC on the prevalence of chronic respiratory diseases (CRD) in Chinese elderly and explore the association in different sub-populations.

METHODS:

Cross-sectional data of demographic characteristics, living environment, smoking-related variables, and CRD were drawn from the Chinese Longitudinal Healthy Longevity Survey in 2018. Multivariate stepwise logistic regression analyses were conducted to examine the association of the TTFC with the prevalence of CRD.

RESULTS:

This study includes 13,208 subjects aged 52 years and older, with a mean age of 85.3 years. Of them, 3,779 participants were ex- or current smokers (44.9% had the TTFC ≤30 minutes, 55.1% >30 minutes) and 1,492 had suffered from CRD. Compared with non-smokers, participants with TTFC ≤30 minutes seemed to have higher prevalence of CRD (OR 1.97; 95% CI, 1.65-2.35) than those with TTFC >30 minutes (OR 1.70; 95% CI, 1.44-2.00), although the difference was statistically insignificant (P_interaction = 0.12). Compared with TTFC >30 minutes, TTFC ≤30 minutes could drive a higher prevalence of CRD among female participants, those aged 90 years and older, urban residents, and ex-smokers (P_interaction < 0.05).

CONCLUSION:

Shorter TTFC relates to higher prevalences of CRD in Chinese older females, those aged 90 years and older, urban residents, and ex-smokers. Delaying TTFC might partially reduce its detrimental impact on respiratory disease in these specific subpopulations.

2020-12-01·Microbial cell factories2区 · 工程技术

A probiotic treatment increases the immune response induced by the nasal delivery of spore-adsorbed TTFC

2区 · 工程技术

ArticleOA

作者: Baccigalupi, Loredana ; Isticato, Rachele ; Mazzoli, Arianna ; Santos, Francisco Denis S ; Iossa, Susanna ; Ricca, Ezio ; Maia, Ana Raquel ; Saggese, Anella ; Leite, Fabio

Abstract:

Background:

Spore-forming bacteria of the Bacillus genus are widely used probiotics known to exert their beneficial effects also through the stimulation of the host immune response. The oral delivery of B. toyonensis spores has been shown to improve the immune response to a parenterally administered viral antigen in mice, suggesting that probiotics may increase the efficiency of systemic vaccines. We used the C fragment of the tetanus toxin (TTFC) as a model antigen to evaluate whether a treatment with B. toyonensis spores affected the immune response to a mucosal antigen.

Results:

Purified TTFC was given to mice by the nasal route either as a free protein or adsorbed to B. subtilis spores, a mucosal vaccine delivery system proved effective with several antigens, including TTFC. Spore adsorption was extremely efficient and TTFC was shown to be exposed on the spore surface. Spore-adsorbed TTFC was more efficient than the free antigen in inducing an immune response and the probiotic treatment improved the response, increasing the production of TTFC-specific secretory immunoglobin A (sIgA) and causing a faster production of serum IgG. The analysis of the induced cytokines indicated that also the cellular immune response was increased by the probiotic treatment. A 16S RNA-based analysis of the gut microbial composition did not show dramatic differences due to the probiotic treatment. However, the abundance of members of the Ruminiclostridium 6 genus was found to correlate with the increased immune response of animals immunized with the spore-adsorbed antigen and treated with the probiotic.

Conclusion:

Our results indicate that B. toyonensis spores significantly contribute to the humoral and cellular responses elicited by a mucosal immunization with spore-adsorbed TTFC, pointing to the probiotic treatment as an alternative to the use of adjuvants for mucosal vaccinations.

8

项与曲伏噻吗相关的新闻（医药）

2025-04-17

·Pharma CMC

兆科眼科将8款眼科产品商业化权益授权Interpharma

4月16日，兆科眼科发布公告，公司已与Interpharma Public Company Limited就于泰国商业化NVK002（一种控制近视加深的创新疗法）；BRIMOCHOL™PF（一种治疗老花眼的创新药物）；以及六款针对青光眼的仿制药（贝美前列素、贝美素噻吗洛尔、拉坦前列素、拉坦噻吗、曲伏前列素及曲伏噻吗）分别订立三份分销及供应协议。根据协议条款，兆科眼科将授予Interpharma于泰国进口、分销、推广、营销及销售该等产品的独家权利。Interpharma将代表兆科眼科取得相关的当地药物注册。该等已签订的协议将让兆科眼科可获得不可退还、不可抵扣的预付款项及按照若干成就获得额外里程碑付款。NVK002是一种用于控制儿童及青少年近视加深的试验性新型外用眼部溶液。NVK002是一项专利配方，成功解决低浓度阿托品的不稳性，此技术在全球均受到知识产权保护。NVK002不含防腐剂，预计保存期逾24个月。BRIMOCHOL™PF为不含防腐剂的每日一次瞳孔调节滴眼液，用于矫正因老花眼而丧失近距离视力的疗法。BRIMOCHOL™PF为固定剂量卡巴胆碱（胆碱制剂）及酒石酸溴莫尼丁（α2－受体促效剂）复方。BRIMOCHOL™PF令瞳孔收缩，产生「针孔效应」，仅让在中央聚焦的光线进入眼球，从而使中短距离的影像更锐利。贝美前列素为一种前列腺素类似物（PGA），用于治疗开角型青光眼及高眼压症。兆科眼科已开发出不含防腐剂的单一剂量贝美前列素滴眼液，为艾伯维旗下Lumigan的仿制药，亦为获中国批准的首款不含防腐剂的单一剂量贝美前列素滴眼液。贝美素噻吗洛尔为一种固定剂量组合滴眼液，含PGA及β受体拮抗剂，可降低眼压。该滴眼液为单药应答不佳或不足的原发性开角型青光及高眼压患者的替代疗法。该药具有多重降眼压途径，可以使对仅含PGA或β受体拮抗剂的滴眼液应答不足的患者实现目标眼压。拉坦前列素为一种PGA单一疗法滴眼液，用于治疗开角型青光眼及高眼压症。根据灼识的资料，拉坦前列素为中国用于治疗开角型青光眼的最常用PGA处方药之一。拉坦噻吗为一种组合PGA及β受体拮抗剂滴眼液，可降低眼压。拉坦噻吗滴眼液为耐药性开角型青光眼的替代疗法。该药具有双重作用机制，可以使对仅含PGA或β受体拮抗剂的滴眼液应答不足的患者实现目标眼压。曲伏前列素为一种PGA单一疗法滴眼液，用于治疗开角型青光眼及高眼压症。根据灼识的资料，曲伏前列素为中国用于治疗开角型青光眼的最常用PGA处方药。曲伏噻吗为一种组合PGA及β受体拮抗剂滴眼液，可降低开角型青光眼或高眼压症成年患者的眼压。曲伏噻吗滴眼液为单药无法达到理想眼压降低效果的开角型青光眼患者的替代疗法。该药具有双重作用机制，可以使对仅含PGA或β受体拮抗剂的滴眼液应答不足的患者的眼压进一步降低。Interpharma由一个拥有丰富药业经验的医疗专业人士团体成立。该团体由全球领先制药公司的前董事、医师、药剂师、营养师及医疗技术人员组成。Interpharma拥有丰富而悠久的药业经验，在医院营养保健品方面名列第一。

引进/卖出

2025-02-14

·米内网

【市场】大涨172%潜力品种，南京药企首家过评

精彩内容近日，国家药监局官网显示，南京海科瑞医药申报的4类仿制药维生素B12滴眼液获批生产，为国内首家视同过评，该产品2024上半年在中国三大终端六大市场（统计范围详见本文末）的销售额增速约达172%。目前31个眼科用药已有企业过评或视同过评，欧康维视、兴齐眼药、齐鲁制药等领跑。维生素B12滴眼液可用于缓解调节性眼疲劳症状。在南京海科瑞医药之前，有4家企业拥有维生素B12滴眼液生产批文，该产品2024上半年在中国三大终端六大市场的销售额增速约达172%。 13家企业的维生素B12滴眼液以新注册分类报产，南京海科瑞医药的产品顺利获批并首家视同过评，浙江莎普爱思药业、四川禾亿制药、成都普什制药、广州大光制药等企业的产品报产在审。近年来随着人口老龄化进程加快、生活方式变化、电子产品的普及等，眼部疾病的发病率及用药需求均在不断提升。米内网数据显示，2023年中国三大终端六大市场眼科用药（化学药）销售额超过150亿元，2024上半年有略微回落。近年来中国三大终端六大市场眼科化药销售情况（单位：万元）来源：米内网综合数据库目前有31个眼科用药已有企业过评或视同过评，玻璃酸钠滴眼液、盐酸莫西沙星滴眼液2个品种竞争激烈，目前均有40家及以上的企业过评或视同过评。此外，氟比洛芬钠滴眼液、盐酸西替利嗪滴眼液、盐酸奥布卡因滴眼液、曲伏噻吗滴眼液等13个品种目前仅1家企业过评或视同过评。眼科用药过评情况来源：米内网中国申报进度（MED）数据库从企业过评情况看，欧康维视生物、沈阳兴齐眼药、齐鲁制药、远大健康、中山万汉制药等领跑，目前分别有10个、9个、8个、8个、8个眼科用药过评或视同过评。资料来源：米内网数据库、国家药监局官网等注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至2月14日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

2025-01-05

·米内网

12月7个1类新药报产，8个品种获批新适应症，17个品种首家过评，这个品种仿制企业达11家

摘要 abstract 2024年12月，7个1类新药、10个改良型新药申报上市；320个品种按新分类仿制申请申报，其中63个品种暂无国内仿制获批，富马酸伏诺拉生片有11家企业提交仿制申请，石家庄四药仿制申报品种数最多，有11个；45个存量品种有企业申报一致性评价，其中1个品种为首次申报；8个1类新药、1个新剂型改良型新药获批上市，8个品种获批新适应症；17个品种首家过评，其中11个为首仿。创新药品种申报情况 2024年12月，200个创新药品种（药品注册分类为“1”的品种）获CDE承办。7个品种申请上市：HH-003注射液(华辉安健(北京)生物)、Rilzabrutinib片(健赞)、培来加南喷雾剂(江苏普莱医药)、仁术健胃颗粒(南京中山制药)、伊诺格鲁肽注射液(杭州先为达生物)、伊坦长效重组人生长激素注射液(YI-MAB BIOTECH)、重组质粒-肝细胞生长因子注射液(武汉光谷人福生物医药)。2024年12月创新药上市申请承办情况2024年12月创新药临床申请承办情况改良型新药品种申报情况 2024年12月，48个改良型新药品种获CDE承办。伯瑞替尼肠溶胶囊(北京浦润奥生物)、布西珠单抗注射液(诺华)、马来酸噻吗洛尔凝胶(北京梅尔森医药)、赛沃替尼片(和记黄埔医药(上海))、替尔泊肽注射液(礼来)、乌帕替尼缓释片(艾伯维)、注射用玛贝兰妥单抗(葛兰素史克)7个品种为新适应症上市申请。2024年12月改良型新药上市申请承办情况2024年12月改良型新药临床申请承办情况新分类仿制药品种申报情况 2024年12月，320个品种仿制申请获CDE承办，其中63个品种在中国境内暂无仿制药获批。富马酸伏诺拉生片申报企业最多，有11家。此外，石家庄四药申报品种最多，有11个。2024年12月新分类仿制药品种申报情况存量品种一致性评价申报情况 2024年12月，45个品种的一致性评价补充申请获CDE承办。盐酸吡格列酮分散片首次有企业按补充申请申报。2024年12月存量品种一致性评价申报情况获批情况 2024年12月有8款1类新药首次获批上市，9个品种获批新适应症，1个新剂型获批。190个品种按新分类仿制申请获批并视同过评，43个品种按存量品种一致性评价补充申请过评。其中，17个品种首家过评，阿帕他胺片、艾曲泊帕乙醇胺干混悬剂、巴氯芬口服溶液、碘比醇注射液、氟比洛芬钠滴眼液、精氨酸培哚普利片、聚乙二醇钠钾散、培哚普利氨氯地平片(Ⅲ)、曲伏噻吗滴眼液、司来帕格片、小儿法罗培南钠颗粒等11个品种为首仿品种。2024年12月主要注册类型品种获批情况数据来源：米内网中国申报进度数据库（MED）、CDE、NMPA；相关统计字段按药品名称统计，申报企业数按主申报企业统计，时间截至2024年12月31日；获批品种按NMPA发布时间统计；药物作用靶点以及适应症整理自公开资料；首仿品种指中国内地首仿品种。本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com 稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

一致性评价上市批准

100 项与曲伏噻吗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	S01ED51	-

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
青光眼	日本	Novartis Pharmaceuticals Corp.	2010-04-16
开角型青光眼	欧盟	Novartis Europharm Ltd.	2006-04-23
开角型青光眼	冰岛	Novartis Europharm Ltd.	2006-04-23
开角型青光眼	列支敦士登	Novartis Europharm Ltd.	2006-04-23
开角型青光眼	挪威	Novartis Europharm Ltd.	2006-04-23
高眼压症	欧盟	Novartis Europharm Ltd.	2006-04-23
高眼压症	冰岛	Novartis Europharm Ltd.	2006-04-23
高眼压症	列支敦士登	Novartis Europharm Ltd.	2006-04-23
高眼压症	挪威	Novartis Europharm Ltd.	2006-04-23

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02730871 (CTgov)	临床4期	开角型青光眼	173	Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension+Travoprost 0.004%/timolol 0.5% solution (Simbrinza + Duotrav)	餘顧壓構簾顧廠齋築鹽(蓋積壓糧積選製憲積願) = 糧鏇繭獵觸淵簾鹽壓鏇壓憲窪積製憲製鑰淵齋 (窪壓積糧鏇憲醖選觸衊, 2.69) 更多	-	2019-05-17
				Brinzolamide/brimonidine vehicle+Travoprost 0.004%/timolol 0.5% solution (Vehicle + Duotrav)	餘顧壓構簾顧廠齋築鹽(蓋積壓糧積選製憲積願) = 憲窪醖鏇鑰憲觸構鑰窪壓憲窪積製憲製鑰淵齋 (窪壓積糧鏇憲醖選觸衊, 3.01) 更多
NCT02003391 (Pubmed \| J Ophthalmol) 人工标引	临床4期	高眼压症 \| 开角型青光眼	156	Travoprost+Timolol	觸鬱壓顧積蓋遞廠憲廠(製願憲壓齋鹽齋鏇衊鹹) = 鬱選膚淵廠鹽範繭壓廠構襯齋觸構衊觸築淵廠 (製艱鑰積醖淵築築構願, 3.1) 更多	积极	2017-01-01
				beta-blocker monotherapy+Travoprost+Timolol	觸鬱壓顧積蓋遞廠憲廠(製願憲壓齋鹽齋鏇衊鹹) = 鹹構蓋願選觸鏇鹹窪壓構襯齋觸構衊觸築淵廠 (製艱鑰積醖淵築築構願, 3.1) 更多
NCT02003391 (CTgov)	临床4期	开角型青光眼	157	Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution (DuoTrav)	鹹簾構廠壓築願簾鏇糧(蓋顧鹽構鏇夢鏇觸構膚) = 觸餘淵鬱餘顧糧餘遞製鑰齋構艱遞壓夢願淵範 (餘範獵憲鑰壓鬱簾憲壓, 蓋範廠鏇製夢膚構鑰襯 ~ 鏇積構壓選顧淵鹽簾醖) 更多	-	2016-08-08
				Beta-blocker monotherapy+Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution (Beta-blocker)	鹹簾構廠壓築願簾鏇糧(蓋顧鹽構鏇夢鏇觸構膚) = 顧壓壓選餘鹹糧壓壓壓鑰齋構艱遞壓夢願淵範 (餘範獵憲鑰壓鬱簾憲壓, 壓範繭選壓網願製廠餘 ~ 網鏇醖襯窪鬱獵鬱選襯) 更多
NCT01547598 (CTgov)	临床4期	开角型青光眼	135	Bimatoprost ophthalmic solution 0.01%+travoprost ophthalmic solution 0.004% (LUMIGAN® RC)	壓鬱獵簾網鏇膚構憲積(鏇齋壓簾範積鹹築鑰願) = 衊艱構衊製齋顧簾遞襯鹽鹽鑰蓋衊願繭齋餘簾 (窪窪夢構築網築築觸鹹, 3.5) 更多	-	2014-08-15
				travoprost ophthalmic solution 0.004%+travoprost 0.004% / timolol 0.5% combination ophthalmic solution (DuoTrav®)	壓鬱獵簾網鏇膚構憲積(鏇齋壓簾範積鹹築鑰願) = 築憲憲範積願餘積醖簾鹽鹽鑰蓋衊願繭齋餘簾 (窪窪夢構築網築築觸鹹, 2.7) 更多
ARVO2014	N/A	青光眼	50	PQ-TTFC	獵範齋觸積糧衊膚齋夢(膚壓選築醖廠蓋壓鏇蓋) = 糧糧鏇鬱襯築壓鏇襯艱廠獵憲憲鑰獵糧觸夢壓 (廠廠顧壓製夢簾憲廠繭 ) 更多	积极	2014-04-01
NCT01327599 (CTgov)	临床4期	青光眼相关色素分散综合征	60	Travoprost 0.004%+Timolol 0.5% ophthalmic solution	觸願廠選網廠餘鏇製壓(選構衊齋顧鏇壓鏇構製) = 範網襯積艱鏇憲鹹選鹹壓艱製醖網餘壓積鹽鏇 (鏇衊顧鬱淵餘壓構網淵, 1.0) 更多	-	2014-01-10
NCT01336569 (CTgov)	临床4期	开角型青光眼	50	Travoprost 0.004%/timolol maleate 0.5% fixed combination	築膚襯鑰襯夢糧齋簾窪(顧糧顧糧獵簾艱鑰獵窪) = 壓鏇鹹窪衊艱遞範衊膚鹹夢壓廠夢鏇廠選積鏇 (願淵憲襯構廠壓艱遞蓋, 3.6) 更多	-	2013-07-08
NCT00508469 (CTgov)	临床4期	开角型青光眼	102	Travalert Dosing Aid+Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav) (Travalert With Travoprost/Timolol Fixed Combination)	襯廠憲顧衊餘膚繭淵顧 = 願遞鏇淵鹽襯夢糧製糧網獵醖膚簾觸齋廠繭鑰 (構觸觸網簾鬱選蓋壓夢, 簾築艱夢膚衊蓋齋鑰鹹 ~ 鹹遞鹹獵憲醖鬱積選積) 更多	-	2012-07-12
				Travalert Dosing Aid+Timolol 0.05% eye drops+Travoprost 0.004% eye drops (Travalert With Travoprost and Timolol)	襯廠憲顧衊餘膚繭淵顧 = 襯鬱窪築膚糧觸鑰網顧網獵醖膚簾觸齋廠繭鑰 (構觸觸網簾鬱選蓋壓夢, 蓋膚選憲觸積獵獵夢壓 ~ 獵襯壓壓蓋壓願衊壓獵) 更多
ARVO2010	N/A	青光眼	45	Travoprost/timolol (Normal subjects)	遞壓壓蓋範窪選鹽醖壓(簾艱膚築構齋繭廠獵蓋) = 網淵鹹遞鑰壓願醖鏇憲廠夢壓壓夢簾築願廠艱 (簾齋壓艱獵築餘願製憲 ) 更多	-	2010-04-01
				Glaucoma patients treated with bimatoprost/timolol	遞壓壓蓋範窪選鹽醖壓(簾艱膚築構齋繭廠獵蓋) = 積積壓鹽製窪襯蓋衊廠廠夢壓壓夢簾築願廠艱 (簾齋壓艱獵築餘願製憲 ) 更多
NCT00887029 (ARVO2010)	临床4期	开角型青光眼	-	Travoprost-Timolol Fixed-Combination	顧構積鹽範壓醖遞鑰鹹(選簾糧膚構遞齋獵範壓) = 鹹鬱顧選範鏇製觸鹹夢選廠鏇鬱簾夢淵醖窪衊 (鑰鏇壓簾觸鹹築夢築鏇 ) 更多	-	2010-04-01
				Latanoprost-Timolol Fixed-Combination	顧構積鹽範壓醖遞鑰鹹(選簾糧膚構遞齋獵範壓) = 積願網鏇構繭觸醖衊窪選廠鏇鬱簾夢淵醖窪衊 (鑰鏇壓簾觸鹹築夢築鏇 ) 更多